z-logo
HomeZAIABlog
open-access-imgOpen Access
Omalizumab-A review
Author(s) -
Kiran Godse,
Aayushi Mehta,
Sharmila Patil,
Manjyot Gautam,
Nitin Nadkarni
Publication year - 2015
Publication title -
indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.160490
Subject(s) - omalizumab , medicine , immunoglobulin e , monoclonal antibody , recombinant dna , antibody , monoclonal , chronic urticaria , immunology , biochemistry , chemistry , gene
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.